Table 2

Subject characteristics at baseline and follow-up

Baseline

Follow-up

Placebo (n = 79)

Vitamins (n = 83)

Placebo (n = 79)

Vitamins (n = 83)


Age (years)

65 ± 11

64 ± 12

69 ± 11

68 ± 12

Sex (male)

56 (71)

61 (73)

56 (71)

61 (73)

Treatment period (years)

-

-

3.8 ± 0.9

4.0 ± 0.9

Stroke type

Ischemic

54 (69)

62 (75)

-

-

TIA

19 (24)

13 (16)

-

-

Haemorrhagic

4 (5)

8 (10)

-

-

Unknown

2 (3)

0 (0)

-

-

Medications

Antiplatelet agent

68 (86)

63 (76)

60 (76)

59 (71)

Warfarin

11 (14)

16 (19)

13 (17)

15 (18)

Statin

24 (32)

30 (36)

59 (75)

56 (68)

Antihypertensive agent

47 (60)

45 (54)

69 (87)

71 (86)

Risk factors

Hypertension*

57 (72)

63 (75)

69 (87)

71 (86)

Hypercholesterolemia

25 (32)

29 (35)

59 (75)

56 (68)

Diabetes

14 (18)

15 (18)

22 (28)

19 (23)

Current smoker

15 (19)

18 (22)

7 (9)

7 (8)

Fruit (pieces/day)

-

-

1.7 ± 1.3

1.6 ± 1.1

Vegetables (serves/day)

-

-

3.5 ± 1.1

3.5 ± 1.2

Clinical characteristics

BMI (kg/m2)

-

-

29.3 ± 4.9

29.1 ± 4.8

Waist circumference (cm)

-

-

103 ± 12

103 ± 13

Systolic BP (mmHg)

135 ± 15

132 ± 16

145 ± 19

140 ± 16

Diastolic BP (mmHg)

78 ± 9

78 ± 10

79 ± 11

78 ± 10

GFR (ml/min/1.73 m2)§

84 ± 19

88 ± 21

79 ± 18

77 ± 24


Values are mean ± standard deviation or number (%)

TIA indicates transient ischemic attack of eye or brain; BMI, body mass index; BP, blood pressure, GFR, glomerular filtration rate.

*History of previous or current hypertension

Treated for hypercholesterolaemia

Includes type I, type II and impaired fasting glycaemia

§Estimated using the Modification of Diet in Renal Disease Study equation [50]

Potter et al. BMC Cardiovascular Disorders 2008 8:24   doi:10.1186/1471-2261-8-24

Open Data